Is Strides Pharma Science Ltd debt-free?

Yes, Strides Pharma Science Ltd is debt-free with a debt-to-equity ratio of 0.38.

Home

Strides Pharma Science Ltd

Strides Pharma Science Ltd Financials

Strides Pharma Science Ltd Financial Statement

Strides Pharma Science Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars	Jun 2025	Mar 2025	Dec 2024
Revenue	500.37	568.08	553.35
Operating Expense	431.39	488.03	476.84
Net Profit	13.35	16.13	14.94
Net Profit Margin	2.67	2.84	2.70
Earning Per Share	1.45	1.75	1.62
EBIDTA	65.89	62.62	75.81
Effective Tax Rate	-0.07	-6.55	7.50

Particulars	Jun 2025
Revenue	500.37
Operating Expense	431.39
Net Profit	13.35
Net Profit Margin	2.67
Earning Per Share	1.45
EBIDTA	65.89
Effective Tax Rate	-0.07

Strides Pharma Science Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
Total Revenue Annual	2,139.42	1,866.12	1,854.50
Operating Expenses Annual	1,876.98	1,715.61	1,756.02
Operating Profit Annual	3,135.66	272.68	167.54
Interest Annual	145.91	139.38	138.68
Depreciation	76.75	84.09	81.71
Net Profit Annual	59.16	-24.28	4.68
Tax Annual	18.93	1.34	-69.44

Particulars	Mar 2025
Total Revenue Annual	2,139.42
Operating Expenses Annual	1,876.98
Operating Profit Annual	3,135.66
Interest Annual	145.91
Depreciation	76.75
Net Profit Annual	59.16
Tax Annual	18.93

Strides Pharma Science Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
Cash Flow at the Beginning	92.75	82.11	12.12
Cash Flow from Operations	421.48	-14.01	241.74
Cash Flow from Investing	-137.59	-68.69	-182.58
Cash Flow from Financing	-370.32	93.34	10.82
Cash Flow at the End	6.33	92.75	82.11

Particulars	Mar 2025
Cash Flow at the Beginning	92.75
Cash Flow from Operations	421.48
Cash Flow from Investing	-137.59
Cash Flow from Financing	-370.32
Cash Flow at the End	6.33

Strides Pharma Science Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
PBDIT Margin (%)	14.43	11.23	9.91
PBIT Margin (%)	10.48	6.55	4.87
PBT Margin (%)	10.41	6.50	4.83
Net PROFIT Margin (%)	134.91	2.39	0.25
Return On Networth / Equity (%)	85.90	1.43	0.61
Return On Networth /Employed (%)	4.62	2.40	1.87
Return On Assets (%)	59.36	0.88	0.10
Total Debt / Equity (X)	0.43	0.44	0.39
Asset Turnover Ratio (%)	0.44	0.37	0.39

Particulars	Mar 2025
PBDIT Margin (%)	14.43
PBIT Margin (%)	10.48
PBT Margin (%)	10.41
Net PROFIT Margin (%)	134.91
Return On Networth / Equity (%)	85.90
Return On Networth /Employed (%)	4.62
Return On Assets (%)	59.36
Total Debt / Equity (X)	0.43
Asset Turnover Ratio (%)	0.44

Strides Pharma Science Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars	Mar 2025	Mar 2024	Mar 2023
Fixed Assets Annual	795.96	771.89	623.89
Total Current Assets Annual	2,145.50	2,411.18	2,126.40
Non Current Assets Annual	2,885.44	3,490.70	3,493.34
Total Shareholders Funds Annual	3,192.74	3,527.60	3,455.05
Total Assets Annual	5,030.95	5,901.87	5,619.74

Particulars	Mar 2025
Fixed Assets Annual	795.96
Total Current Assets Annual	2,145.50
Non Current Assets Annual	2,885.44
Total Shareholders Funds Annual	3,192.74
Total Assets Annual	5,030.95

Strides Pharma Science Ltd Earning Calls

EPS (INR)

Expected

10.81

Reported

10.81

Surprise

0.00%

Mar 2025

EPS beaten by 0.00%

Dec 2024

EPS beaten by 0.00%

Sep 2024

EPS beaten by 0.21%

Dividend Pages

PE Ratio

FAQS on Strides Pharma Science Ltd Financials

As of Oct 29, 2025, Strides Pharma Science Ltd has a market capitalization of 6,165.69 Cr. Value Research classifies it as a Mid-Cap company.

Yes, Strides Pharma Science Ltd is with a debt-to-equity ratio of 0.38.

In FY 2024 , Strides Pharma Science Ltd recorded a total revenue of approximately 2,139.42 Cr marking a significant milestone in the company's financial performance.

Strides Pharma Science Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.4% and 0.1% annually, respectively..

Strides Pharma Science Ltd's current PE ratio is 2.14.

Strides Pharma Science Ltd's ROCE averaged 3.1% from the FY ending March 2023 to 2025, with a median of 2.3%. It peaked at 5.1% in March 2025, reflecting strong capital efficiency over the period..

Strides Pharma Science Ltd's latest EBIT is Rs. 3,051.05 Cr, surpassing the average EBIT of Rs. 1,103.41 Cr over the 5 years..